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Drug-drug interactions (DDIs) remain one of the chal-
lenges faced by health care professionals involved in
patient management and by researchers seeking to under-
stand the many different mechanisms that may be
involved. While in HIV treatment there has been an
understanding that checking for DDIs is part of routine
management, the development of directly acting antiviral
(DAA) drugs is changing the whole approach to the treat-
ment of HCV. DDIs have not really been high on the
agenda while pegylated interferon and ribavirin have been
the standard of care for Hepatitis C; however the first gen-
eration HCV protease inhibitors while representing a huge
advance, also present new treatment challenge of aware-
ness and management of DDIs.
In this presentation, some of the key areas of DDIs with
a) HIV drugs, b) HCV drugs and c) co infected patients
receiving both HIV and HCV drugs will be discussed.
While it has long been established that boosted HIV pro-
tease inhibitors are likely to interact with other medica-
tions metabolised by CYP3A4 (and other enzymes/
transporters) to increase drug exposure and that drugs like
efavirenz, nevirapine and etravirine are inducers of drug
metabolism some of the current challenges are to deter-
mine i) the likelihood of interactions where there are no
study data to guide us and ii) what happens when a patient
switches therapy off an enzyme inducing drug. In relation
to the new DAAs, Boceprevir is primarily metabolised by
the enzyme aldo-ketoreductase (AKR) but also undergoes
metabolism by CYP3A4; telaprevir is metabolised
by CYP3A4. In addition, both boceprevir and telaprevir
are strong inhibitors of CYP3A4 and are substrates for
P-glycoprotein. Co administration of drugs that are highly
dependent on CYP3A4 for clearance and for which ele-
vated plasma concentrations are associated with serious or
life threatening events means a contraindication with
boceprevir and/or telaprevir. However, many other inter-
actions require close monitoring, alteration of drug dosage
or timing of administration and here we clearly need help
to understand the potential magnitude of an interaction
and strategies for patient management. Since targeted
drug interaction studies are done in the development pro-
gramme and then post-licensing there are a limited num-
ber of drugs for which there are actual study data. Where
there are no data, guidance can only be given based on
knowledge of the pharmacology of the respective drugs.
This is the approach being used in the resource http://
www.hep-druginteractions.org.
One particular area of concern is HIV positive patients
who are receiving antiretrovirals (ARVs) since they are
relatively highly represented among patients with HCV
infection, and are at a high risk of DDIs. Recent drug
interaction data presented on telaprevir and boceprevir
have reinforced the initial suspicions that we are faced
with a whole new challenge of managing multiple inter-
actions in co-infected patients.
Management of DDIs with these exciting new agents
certainly poses a challenge and awareness of the potential
for DDIs is fundamental for safe prescribing. Think DDIs
for the DAAs. But we are still on a steep learning curve
and there are unanswered questions.
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